

Notice of revision of consolidated performance forecast

The consolidated performance forecast for fiscal 2022 (April 1, 2022 – March 31, 2023) announced on November 9, 2022, has been revised as shown below based on recent performance trends.

1. Revision of consolidated forecast

	Net sales (¥ million)	Operating income (¥ million)	Ordinary income (¥ million)	Net income attributable to owners of the parent (¥ million)	Net income per share (¥)
Previous forecast	2,851,000	177,000	178,000	129,000	92.98
Revised forecast	2,737,000	125,000	118,000	70,000	50.46
Increase (decrease)	(114,000)	(52,000)	(60,000)	(59,000)	—
Percent change	-4.0%	-29.4%	-33.7%	-45.7%	—
cf. fiscal 2021	2,461,317	202,647	212,052	161,880	116.68

2. Reason for revision

Net sales, operating income, and ordinary income are expected to be lower than previously forecasted as the performance of Basic Materials and Digital Solutions in the Material segment is expected to deteriorate due to the prolonged shortage of semiconductors, lockdowns in China, decreased demand due to economic slowdown, and lower petrochemical market prices, while the Health Care segment is expected to be impacted by delayed recovery of earnings in the Critical Care business. Net income attributable to owners of the parent is expected to fall short of the previous forecast due to a delay in the beneficial tax effect from reconfiguration of organizations related to Veloxis Pharmaceuticals, Inc. in the Health Care segment, in addition to the aforementioned factors.

Note: This forecast is based on the best information available at this time, but actual outcomes may differ due to a variety of factors which cannot be foreseen.

For more information, please contact:

Asahi Kasei Corp.

Corporate Communications

Phone: +81-(0)3-6699-3008

Fax: +81-(0)3-6699-3187